Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview at the following investment conferences:

-- Deutsche Bank's 33rd Annual Healthcare Conference at the

InterContinental Hotel in Boston on Tuesday, May 6, 2008 at 2:10pm

Eastern Time (11:10am Pacific Time)

-- Bank of America's 2008 Healthcare Conference at the Four Seasons Hotel

in Las Vegas on Wednesday, May 14, 2008 at 4:00pm Pacific Time (7:00pm

Eastern Time)

-- JMP Securities' Seventh Annual Research Conference at the Ritz-Carlton

Hotel in San Francisco on Wednesday, May 21, 2008 at 12:00pm Pacific

Time (3:00pm Eastern Time)

Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentations, click on the Investor Relations tab the link entitled "Events and Presentations" on the left side of the screen. A replay of each webcast will available approximately one hour after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in developme
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
3. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
4. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
10. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... BALTIMORE , May 21, 2013  Personal ... will use its proprietary methodologies and expertise in ... novel kinase targets in collaboration with Blueprint Medicines. ... aimed at identifying genomic alterations in tumors, and ... selective kinase inhibitors for a genetically defined patient ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 ... at the University of California, San Diego for a ... load bearing Gravitic™ MRI (Magnetic Resonance Imaging) with that ... renowned for its continued pursuit of improved healthcare by ... Spinal MRI is an extremely valuable tool for evaluating ...
(Date:5/21/2013)... 21, 2013 Clinovo's new “CDISC ... training program starting on June 11th, 2013. The TechTrainings ... professionals reach the next step in their professional career. ... Palo Alto, and streamed online. , Taught by Sy ... Clinovo's new “CDISC Standards: Theory and Application” class will ...
(Date:5/20/2013)... ANGELES , May 20, 2013 Today, ... San Francisco , James McGough ... Clinical Psychiatry at the Semel Institute for Neuroscience and ... of Medicine at the University of California Los ... both Child and Adolescent Psychopharmacology and ADHD at UCLA, ...
Breaking Biology Technology:Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3Clinovo Launches TechTrainings on CDISC Standards 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5
... System will Allow Bedside Detection of Ischemic ... Events and Myocardial Infarction (Heart Attack), TEL AVIV, ... Israeli company which develops and markets systems for,non-invasive diagnosis ... detecting ischemic events using its proprietary,HyperQ technology in resting ...
... to Head Rapid Sales Growth of Leading DR and ... Image and Data Management ... Systems, a,leading developer of digital radiography (DR), PACS (Picture Archiving ... today announced it has appointed Robert Royea as,vice president of ...
... BioStorage Technologies, Inc.,(BST), announces the appointment of ... European operations in Griesheim, Germany. Hoffer,joins BST with ... fields of,clinical pharmacology and toxicology. In his new ... Chief Operating Officer for BST, and will,manage all ...
Cached Biology Technology:BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study 2Royea Joins Eklin Medical Systems as VP of Worldwide Sales 2Royea Joins Eklin Medical Systems as VP of Worldwide Sales 3BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations 2
(Date:5/18/2013)... (May 18, 2013) Research presented today at Digestive ... research, with findings about the impact of coffee on ... , While coffee consumption recently has been associated with ... even a few more cups of java each month ... liver disease. Researchers at the Mayo Clinic, Rochester, MN, ...
(Date:5/17/2013)... Rutgers, The State University of New Jersey, and City ... formulation called Visikol TM that effectively clears organisms ... in place of chloral hydrate, which is one of ... is tightly regulated by the Drug Enforcement Administration (DEA) ... solutions, or clearing agents, are vital for viewing organisms ...
(Date:5/17/2013)... study finds human-caused climate change may have little ... a host of recent studies that predict their ... The findings, which appear in the journal ... survival of a creature thought to be doomed: ... cold-blooded animals, especially forest lizards, will be hard ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
... streams and rivers has been significantly altered in nearly ... new nationwide USGS study. Flow alterations are a ... native species. "This USGS assessment provides the ... alteration," said Bill Werkheiser, USGS Associate Director for Water. ...
... JOLLA, CA--The Salk Institute for Biological Studies and Columbia ... grant by The Leona M. and Harry B. Helmsley ... use of induced pluripotent stem (iPS) cells to gain ... therapeutic drugs. "Stem cell research is of immense ...
... built-in timer intended to improve the accuracy of paper ... and elsewhere. Their study appears in ACS, semi-monthly journal ... Hyeran Noh note that so-called point-of-care tests include paper ... instead of in laboratories. They show special promise for ...
Cached Biology News:Most river flows across the US are altered by land and water management 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 3Built-in timer for improving accuracy of cost saving paper-strip medical tests 2
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Biology Products: